Aggressive fluid and sodium restriction in decompensated heart failure with preserved ejection fraction: Results from a randomized clinical trial

被引:28
|
作者
Machado d'Almeida, Karina Sanches [1 ,2 ,3 ]
Rabelo-Silva, Eneida Rejane [1 ,3 ,4 ]
Souza, Gabriela Correa [3 ,5 ]
Trojahn, Melina Maria [3 ]
Santin Barilli, Sofia Louise [3 ]
Aliti, Graziella [3 ,4 ]
Rohde, Luis Eduardo [1 ,3 ,5 ]
Biolo, Andreia [1 ,3 ,5 ]
Beck-da-Silva, Luis [1 ,3 ]
机构
[1] Univ Fed Rio Grande do Sul, Post Grad Program Hlth Sci Cardiol & Cardiovasc S, Porto Alegre, RS, Brazil
[2] Univ Fed Pampa, UNIPAMPA, Nutr Program, Itaqui, RS, Brazil
[3] Hosp Clin Porto Alegre, Heart Failure & Transplant Grp, Porto Alegre, RS, Brazil
[4] Univ Fed Rio Grande do Sul, Sch Nursing, Porto Alegre, RS, Brazil
[5] Univ Fed Rio Grande do Sul, Sch Med, Dept Internal Med, Porto Alegre, RS, Brazil
关键词
Heart failure; Preserved ejection fraction; Diastolic; Sodium restriction; Fluid restriction; DIET; MANAGEMENT; SALT; IMPACT;
D O I
10.1016/j.nut.2018.02.007
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Objectives: Sodium and fluid restriction is commonly prescribed for heart failure patients. However, its role in the treatment of heart failure with preserved ejection fraction (HFpEF) remains unclear. The aim of this study was to compare the effect of a diet with sodium and fluid restriction with an unrestricted diet in patients admitted for decompensated HFpEF. Methods: Patients were randomized to a diet with sodium (0.8 g/d) and fluid (800 mL/d) restriction (intervention group [IG]) or an unrestricted diet (control group [CG]) and followed for 7 d or hospital discharge. The primary outcome was weight loss. Secondary outcomes included clinical stability, perception of thirst, neurohormonal activation, nutrient intake, readmission, and mortality rate after 30 d. Results: Fifty-three patients were included (30, IG; 23, CG). The mean ejection fraction was 62% +/- 8% for IG and 60% +/- 7% for CG (P = 0.44). Weight loss was similar in both groups, being 1.6 +/- 2.2 kg in the IG and 1.8 +/- 2.1 kg in CG (P= 0.49) as well as the reduction in the congestion score (IG = 3.4 +/- 3.5; CG = 3.8 +/- 3.4; P = 0.70). The daily perception of thirst was higher in the IG (P = 0.03). Lower energy consumption was seen in the IG (P < 0.001). No significant between-group differences at 30 d were found. Conclusions: Aggressive sodium and fluid restriction does not provide symptomatic or prognosis benefits, but does produce greater perception of thirst, may impair the patient's food intake, and does not seem to have an important neurohormonal effect in patients admitted for decompensated HFpEF. (C) 2018 Elsevier Inc. All rights reserved.
引用
收藏
页码:111 / 117
页数:7
相关论文
共 50 条
  • [41] Atrial Fibrillation Ablation for Heart Failure With Preserved Ejection Fraction A Randomized Controlled Trial
    Chieng, David
    Sugumar, Hariharan
    Segan, Louise
    Tan, Caleb
    Vizi, Donna
    Nanayakkara, Shane
    Al-Kaisey, Ahmed
    Hawson, Joshua
    Prabhu, Sandeep
    Voskoboinik, Aleksandr
    Finch, Sue
    Morton, Joseph B.
    Lee, Geoffrey
    Mariani, Justin
    La Gerche, Andre
    Taylor, Andrew J.
    Howden, Erin
    Kistler, Peter M.
    Kalman, Jonathan M.
    Kaye, David M.
    Ling, Liang-Han
    JACC-HEART FAILURE, 2023, 11 (06) : 646 - 658
  • [42] Relationship between osteoprotegerin and mortality in decompensated heart failure with preserved ejection fraction
    Aramburu-Bodas, Oscar
    Garcia-Casado, Beatriz
    Salamanca-Bautista, Prado
    Guisado-Espartero, Maria E.
    Arias-Jimenez, Jose L.
    Barco-Sanchez, Antonio
    Carlos Santamaria-Gonzalez, Juan
    Formiga, Francesc
    Montero-Perez-Barquero, Manuel
    Manzano, Luis
    JOURNAL OF CARDIOVASCULAR MEDICINE, 2015, 16 (06) : 438 - 443
  • [43] Body Mass Index and Adverse Cardiovascular Outcomes in Heart Failure Patients With Preserved Ejection Fraction Results From the Irbesartan in Heart Failure With Preserved Ejection Fraction (I-PRESERVE) Trial
    Haass, Markus
    Kitzman, Dalane W.
    Anand, Inder S.
    Miller, Alan
    Zile, Michael R.
    Massie, Barry M.
    Carson, Peter E.
    CIRCULATION-HEART FAILURE, 2011, 4 (03) : 324 - 331
  • [44] The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction Results From the I-PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction)
    Carson, Peter E.
    Anand, Inder S.
    Win, Sithu
    Rector, Thomas
    Haass, Markus
    Lopez-Sendon, Jose
    Miller, Alan
    Teerlink, John R.
    White, Michel
    McKelvie, Robert S.
    Komajda, Michel
    Zile, Michael R.
    McMurray, John J.
    Massie, Barry
    JACC-HEART FAILURE, 2015, 3 (06) : 429 - 441
  • [45] Anemia in Heart Failure With Preserved Ejection Fraction: Insights From the TOPCAT trial
    O'Meara, Eileen
    Kenwood, Christopher T.
    Anand, Inder S.
    Desai, Akshay S.
    De Denus, Simon
    Sweitzer, Nancy K.
    Fleg, Jerome L.
    Thao Huynh
    McKinley, Sonja M.
    Pitt, Bertram
    Pfeffer, Marc A.
    Rouleau, Jean L.
    CIRCULATION, 2015, 132
  • [46] The application of lung ultrasound in acute decompensated heart failure in heart failure with preserved and reduced ejection fraction
    Yang, Feifei
    Wang, Qiushuang
    Zhi, Guang
    Zhang, Liwei
    Huang, Dangsheng
    Shen, Dong
    Zhang, Meiqing
    ECHOCARDIOGRAPHY-A JOURNAL OF CARDIOVASCULAR ULTRASOUND AND ALLIED TECHNIQUES, 2017, 34 (10): : 1462 - 1469
  • [47] Difference in pattern of mortality between heart failure with reduced ejection fraction and heart failure with preserved ejection fraction after hospitalization for acute decompensated heart failure
    Nakashima, M. Mitsutaka
    Sakuragi, S.
    EUROPEAN JOURNAL OF HEART FAILURE, 2018, 20 : 424 - 424
  • [48] Epidemiology of heart failure with preserved ejection fraction: Results from the RICA Registry
    Trullas, Joan Carles
    Perez-Calvo, Juan Ignacio
    Conde-Martel, Alicia
    Iborra, Pau Llacer
    Pedreira, Ivan Suarez
    Ormaechea, Gabriela
    Rangel, Llanos Soler
    Franco, Alvaro Gonzalez
    Cepeda, Jose Maria
    Montero-Perez-Barquer, Manuel
    MEDICINA CLINICA, 2021, 157 (01): : 1 - 9
  • [49] Baseline Plasma NT-proBNP and Clinical Characteristics: Results From the Irbesartan in Heart Failure With Preserved Ejection Fraction Trial
    McKelvie, Robert S.
    Komajda, Michel
    McMurray, John
    Zile, Michael
    Ptaszynska, Agata
    Donovan, Mark
    Carson, Peter
    Massie, Barry M.
    JOURNAL OF CARDIAC FAILURE, 2010, 16 (02) : 128 - 134
  • [50] Innovative Clinical Trial Designs for Precision Medicine in Heart Failure with Preserved Ejection Fraction
    Shah, Sanjiv J.
    JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH, 2017, 10 (03) : 322 - 336